Compare Equinix Inc (EQIX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Recursion Pharmaceuticals Inc — how do they compare? Equinix Inc trades at $1,014.93 (market cap $99.77B), while Recursion Pharmaceuticals Inc trades at $4.06 (market cap $2.14B). The key difference: Equinix Inc is far larger — about 46.6× Recursion Pharmaceuticals Inc's market cap, and Equinix Inc pays a 2.04% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EQIX | RXRX | |
|---|---|---|
Market Cap | $99.77B | $2.14B |
Volume | 480,425 | 30,789,535 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $6.79 |
52-Week Low | $726.09 | $2.84 |
Typical Hold Time | 110 Days | 22 Days |
Enterprise Value | $120.90B | $1.66B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,031.77, down 1.49% on the day, amid a bullish technical setup with support at $1,025 and resistance at $1,042. The company reported revenue growth to $9.22B in 2025 and a net income margin of 15.63%, though it missed EPS estimates in two of the last three quarters. Recent news highlights strong AI-driven demand for data centers, with Equinix planning $5B-$7B in annual investments to expand capacity.
Outlook remains positive given analyst consensus of a $1,250 price target and 75% buy ratings, but risks include high valuation multiples (P/E 65.07) and rising debt-to-asset ratio (47.13% in 2025). The stock offers growth exposure to AI infrastructure trends, yet investors should weigh capex intensity against earnings sustainability.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
